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logical types of group A streptococcal M protein, epidemiological studies indicate that only a limited number of M protein
serotypes are associated with ARF outbreaks (6). This finding
suggests that certain M protein serotypes may be more rheumatogenic than others. In a previous attempt to classify streptococcal serotypes according to their rheumatogenic capacity,
Widdowson identified human antisera directed to a non-typespecific protein moiety of M protein known as M-associated
protein (44, 45). However, a more recent classification scheme
has been proposed by Bessen and colleagues, in which streptococcal serotypes were grouped based on the expression of a
conserved surface-exposed M protein epitope (4). It was demonstrated that the M serotypes associated with the majority of
ARF outbreaks possessed an epitope (class I) defined by
monoclonal antibody (MAb) probes 10B6 and 10F5. The sequence of the 10B6 and 10F5 epitope was localized to a 15amino-acid fragment within the C repeat region of the type 6
M protein (23). The remaining serotypes (class II) lack this
epitope or the determinant is structurally inaccessible in those
strains. There was a close parallel between serotypes designated class I and those serotypes previously classified as Massociated protein I by Widdowson (44, 45). The fact that only
certain serotypes within class I streptococci are rheumatogenic
implies that these organisms are of a phenotype that is capable
of inducing ARF (4). This implication is supported in part by
a recent publication in which it was shown that sera of ARF
patients contained high levels of antibodies to the class I
epitope, suggesting that their disease was the result of an
infection by a class I streptococcus (5).
Elevated titers of antibodies to many streptococcal antigens
(2), including M protein and the self-antigen myosin (12–15,
17, 29), are associated with ARF. While antibodies to M protein are crucial for the opsonization of streptococci, they have
also been implicated in the immunological cross-reactions between streptococci and host tissue antigens such as cardiac

Acute rheumatic fever (ARF) is an inflammatory disease
that can follow group A streptococcal pharyngitis. The most
serious clinical manifestation is rheumatic carditis; however,
arthritis, chorea, erythema marginatum, or subcutaneous nodules may be present (40, 41). The pathogenesis of ARF is
thought to be mediated by autoimmune mechanisms activated
during a streptococcal infection (40). The autoimmune hypothesis is supported by a number of previous observations, including a time interval of at least 3 weeks between the initial
streptococcal throat infection and the onset of ARF (40, 41),
the identification of heart-reactive immunoglobulin (Ig) and
complement deposits in the myocardium of patients with fatal
rheumatic carditis (25–27, 30), and the elevation of heartreactive antibodies in the sera of patients with ARF (46).
Cardiac myosin has been identified as one of the cardiac antigens recognized by these heart-reactive antistreptococcal autoantibodies (13, 29).
Streptococcal M protein, an a-helical coiled-coil protein,
structurally and immunologically mimics host tissue antigens,
particularly the rod region of myosin (12, 14, 15, 17, 34, 35).
Sequence analysis has revealed that streptococcal M proteins
contain blocks of internally repeated amino acid sequences
referred to as A, B, and C repeat regions (19). The NH2terminal nonrepeat and A repeat regions contain determinants
of type specificity, while epitopes found in the B and more
highly conserved C repeat regions may be common to different
M serotypes (19). While there are nearly 100 different sero* Corresponding author. Mailing address: Department of Microbiology and Immunology, University of Oklahoma Health Sciences Center, 940 Stanton L. Young Blvd., P.O. Box 26901, Oklahoma City, OK
73104. Phone: (405) 271-2133. Fax: (405) 271-3117. E-mail: madeleine
-cunningham@ouhsc.edu.
† Present address: La Jolla Institute for Allergy and Immunology,
San Diego, CA 92121.
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The class I epitope of streptococcal M protein is an epidemiological marker for acute rheumatic fever
(ARF)-associated serotypes of group A streptococci and is recognized by anti-M protein monoclonal antibody
(MAb) 10B6. Using MAb 10B6, we determined the relationship between the class I epitope of M protein and
the a-helical coiled-coil protein myosin. MAb 10B6 reacted by enzyme-linked immunosorbent assay and
Western blotting with human cardiac myosin and rabbit skeletal myosin and its heavy meromyosin (HMM)
subfragment. Overlapping synthetic peptides of M5 protein were used to identify the region of M5 protein
recognized by MAb 10B6. Two C repeat peptides (C2A and C3) containing the amino acid sequence KGL
RRDLDASREAK reacted with MAb 10B6. Partial sequence identity, RRDL, was found in the HMM fragment
of myosin, which reacted with MAb 10B6. However, not all peptides of M5 protein and myosin containing the
RRDL sequence reacted with MAb 10B6. ARF sera and sera from uncomplicated pharyngitis (UNC) reacted
with C repeat region peptides of M protein, while acute glomerulonephritis sera were not as reactive. Affinitypurified human antibody to peptide C3 reacted with myosin. The data demonstrate that the class I epitope of
M protein is immunologically cross-reactive with myosin and the HMM subfragment, and antibodies to peptide
C3 and myosin were present in ARF and UNC sera.
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MATERIALS AND METHODS
Human sera and antibodies. Sera from 12 patients with ARF were from the
Oklahoma Children’s Heart Center, University of Oklahoma Health Sciences
Center, Oklahoma City, Oklahoma, while poststreptococcal acute glomerulonephritis (AGN) sera were provided by Barry Gray, Department of PediatricsInfectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama. Sera from 12 patients with uncomplicated streptococcal pharyngitis
(UNC) were provided by Penelope Shackelford, Department of Pediatrics—
Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri. Sera from 9 patients with nonrheumatic myocarditis were supplied by Noel
Rose and Eyal Taylor, Department of Microbiology and Immunology, Johns
Hopkins University, Baltimore, Maryland. Eight normal human serum samples
(anti-streptolysin O [ASO], ,50 Todd units) were obtained from the Oklahoma
Children’s Hospital. The normal human serum pool was obtained from the local
blood bank from five healthy individuals. MAb 10B6, a mouse anti-M protein
antibody, was previously produced, characterized, and described (23).
Antigens and peptides. Cardiac myosin was purified from human heart muscle
as previously described by Dell et al. and Tobacman and Adelstein (18, 42).
Briefly, heart tissue was minced and homogenized on ice in 40 mM KCl, 20 mM
imidazole-HCl (pH 7.0), 5 mM EGTA, 5 mM dithiothreitol, 0.5 mM phenylmethylsulfonyl fluoride (PMSF) per ml, and 1 mg of leupeptin for 15 s. The
washed myofibrils were collected by centrifugation at 16,000 3 g for 10 min,
resuspended in extraction buffer (0.3 M KCl, 0.15 M K2HPO4 [pH 7.0], 1 mM
EGTA, 5 mM dithiothreitol, 0.5 mM PMSF, 1 mg of leupeptin per ml, 5 mg of

TABLE 1. Reactivity of MAb 10B6 with overlapping synthetic
peptides of streptococcal M5 protein
Peptidea

Sequence

Residues

Reactivity of MAb
10B6 (20 mg/ml)

NT1
NT2
NT3
NT4
NT4–5
NT5
NT5–6
NT6
NT7
NT8
B1A
B1B
B1B2
B2
B2B3A
B3A
B2B3B
B3B
C1A
C1B
C1C2
C2A
C2B
C2C3
C3

AVTRGTINDPQRAKEALD
KEALDKYELENHDLKTKN
LKTKNEGLKTENEGLKTE
GLKTENEGLKTENEGLKTE
GLKTEKKEHEAENDKLK
KKEHEAENDKLKQQRDTL
DKLKQQRDTLSTQKETLE
QRDTLSTQKETLEREVQN
REVQNTQYNNETLKIKNG
KIKNGDLTKELNKTRQEL
TRQELANKQQESKENEKAL
ENEKALNELLEKTVKDKI
VKDKIAKEQENKETIGTL
TIGTLKKILDETVKDKIA
KDKIAKEQENKETIGTLK
IGTLKKILDETVKDKLAK
DKLAKEQKSKQNIGALKQ
GALKQELAKKDEANKISD
NKISDASRKGLRRDLDAS
DLDASREAKKQLEAEHQK
AEHQKLEEQNKISEASRK
EASRKGLRRDLDASREAK
SREAKKQLEAEQQKLEEQ
KLEEQNKISEASRKGLRR
KGLRRDLDASREAKKQ

1–18
14–31
27–44
40–58
54–70
59–76
67–84
72–89
85–102
98–115
111–129
124–141
137–154
150–167
163–180
176–193
189–206
202–219
215–232
228–245
241–258
254–271
267–284
280–297
293–308

0.05
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.06
0.00
0.00
1.62
0.00
0.00
1.64

a
Peptides are listed in numerical order from the beginning of the mature
protein (33, 36).

N-a-tosyl-lysine-L-chloromethyl ketone [TLCK] per ml), and homogenized on
ice three times for 30 s each. The homogenate was incubated on ice for 30 min
and clarified by centrifugation at 16,000 3 g for 10 min. The extracted actomyosin was precipitated from the supernatant by adding 10 volumes of cold distilled
water and adjusting the pH to 6.5. Actomyosin was collected by centrifugation at
16,000 3 g for 10 min and resuspended in a minimal volume of extraction buffer.
With gentle stirring, KCl was added to a final concentration of 0.5 M, and
ammonium sulfate was added to 33% to facilitate actin precipitation. Once the
suspension was homogeneous, MgCl2 and ATP were added to 5 and 10 mM,
respectively, and then actin was removed by immediate centrifugation at
20,000 3 g for 15 min. The soluble myosin was stored at 4°C in the presence of
the protease inhibitors 0.5 mM PMSF, 1 mg of leupeptin per ml, and 5 mg of
TLCK per ml, which were present in all preparations of the myosin. Purified
rabbit skeletal myosin, tropomyosin, light meromyosin, and heavy meromyosin
were purchased from Sigma Chemical Co. (St. Louis, Mo.). The purity of all
proteins was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western immunoblotting with antigen-specific antibodies. Synthetic, overlapping peptides corresponding to the sequence of the type 5 streptococcal M protein Streptococcus pyogenes Manfredo (18) were synthesized by
Ken Jackson (Molecular Biology Resource Facility, St. Francis Hospital of Tulsa
Medical Research Institute, Oklahoma City, Okla.). The M5 peptides were 16 to
19 amino acids long (Table 1) and were chemically synthesized on a DuPont
RAMPS manual synthesizer by the fluorenylmethoxycarbonyl strategy (8). The
peptides were purified by high-pressure liquid chromatography (32), and the
amino acid composition was confirmed by quantitative amino acid analysis.
ELISA. Assays were performed in Immulon 4 96-well microtiter plates (Dynatech, Chantilly, Va.) coated with antigen (10 mg/ml) overnight at 4°C. Plates
were washed three times with phosphate-buffered saline (PBS)–0.05% Tween 20
and then blocked for 1 h with 1% bovine serum albumin in wash buffer. Test
antibody was added to wells (serum, 1:100; MAb, 10 mg/ml) and incubated
overnight at 4°C. Plates were washed, and goat anti-mouse Ig or goat anti-human
Ig conjugated to alkaline phosphatase (Sigma) was added for 2 h at 37°C. Plates
were washed with PBS-Tween buffer, and p-nitrophenyl phosphate (Sigma) was
added as the enzyme substrate (1 mg/ml) in diethanolamine buffer as described
previously (12, 14). After 30 min, the absorbance was read at 410 nM on a
Dynatech enzyme-linked immunosorbent assay (ELISA) plate reader.
The competitive inhibition ELISA has been previously described (12, 14).
Briefly, antibody was preincubated 1:1 with inhibitor for 1 h at 37°C and then
overnight at 4°C. Forty microliters of the antibody-inhibiting mixture was added
to the antigen-coated wells (50 ml of 10 mg/ml), and the ELISA was carried out
as described. The percentage of inhibition was calculated according to the formula 100 3 (A410 of well with MAb plus buffer 2 A410 of well with MAb plus
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myosin (12–15, 17, 29). In earlier studies, many of these crossreactive epitopes have been localized to the N-terminal, hypervariable A and B repeat regions of the M molecule (12, 15,
17). Myosin-reactive antibodies, found to be elevated in almost
all cases of ARF (13), have been shown to bind to human heart
tissue and to cross-react with streptococcal M protein (12).
Previous studies have demonstrated that immunization of animals with the cell walls of certain strains of group A streptococci resulted in the production of heart-reactive antibodies
which could be adsorbed with streptococcal extracts containing
streptococcal M protein (16, 24, 28). Human MAbs or myosin
affinity-purified antibodies produced from patients with ARF
cross-reacted with streptococcal M protein and human cardiac
myosin and contributed to the presence of heart-cross-reactive
antistreptococcal antibodies in ARF (12, 13, 39). More recent
studies have identified cytotoxic antistreptococcal/antimyosin
MAbs from rheumatic carditis patients (1). Antimyosin antibody has been shown to deposit in the heart tissues of susceptible mice (31), and a cytotoxic mouse antistreptococcal/antimyosin antibody which binds to the surface of heart cells and
to the a-helical coiled coil molecule laminin has been described (10).
Identification of myosin cross-reactive epitopes of M protein
recognized in ARF has been reported for the amino-terminal
half of the molecule (12, 15, 17), and a study by Vashishtha and
Fischetti demonstrated antimyosin antibody responses to the C
repeat region. However, the reactivity was directed only to
denatured myosin (43). More recently, studies of the C repeat
or carboxy-terminal region of M protein have shown T-cell
cross-reactions with myosin (38). The goal of the present study
was to investigate the possibility that the class I epitope in the
C repeat region of M protein cross-reacts immunologically
with myosin. In this study we show that MAb 10B6, which
recognizes the class I epitope of M protein, reacts with cardiac
and skeletal myosin. This study also demonstrates that ARF
and UNC sera react with a site in the conserved C repeat
region of M protein within the class I epitope of rheumatogenic M protein serotypes. The new data show that in addition
to previously described N-terminal epitopes, the class I epitope
of streptococcal M protein is immunologically cross-reactive
with myosin.
(Portions of this work were presented at the XIII International Lancefield Society Meeting on Streptococci and Streptococcal Diseases at the Pasteur Institute in Paris, France, in
September 1996.)
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RESULTS
MAb 10B6 recognizes M5 protein peptides C2A and C3.
Anti-M protein MAb 10B6 recognizes the rheumatic feverassociated class I M protein epitope described by Bessen and
colleagues (4). Furthermore, Jones and colleagues (23) identified a 15-amino-acid peptide within the conserved region of
the M6 protein that contained the MAb 10B6 epitope. For
identification of the epitope within the M5 protein recognized
by MAb 10B6, it was reacted with 23 overlapping synthetic
peptides of the type 5 streptococcal M protein by ELISA. The
synthesized M5 peptides represent the amino-terminal and A
repeat (NT), B repeat (B), and C repeat (C) regions of the M5
molecule (Table 1). Table 1 shows the reaction of anti-M
protein MAb 10B6 with streptococcal M5 peptides in the
ELISA. The M5 protein peptides were used in the ELISA to
determine the M protein epitopes recognized by a MAb to the
class I M protein epitope (10B6, 20 mg/ml). The M5 peptides
recognized by MAb 10B6 were peptides C2A and C3 (Table 1).
At least four repetitive assays performed in duplicate have
verified that these two peptides react with MAb 10B6 by
ELISA. A control antibody did not react with these peptides.
This highly repeatable result identified the M5 peptides containing the class I epitope. The strong recognition of these two
nonadjacent C repeat region peptides can best be explained by
the identity in their amino acid sequences: peptides C2A and
C3 both contain the sequence KGLRRDLDASREAK (Table
1). The N-terminal half of this peptide shows identity with the
10B6 epitope described by Jones et al. in the M6 protein (23).
Because some M protein epitopes have been shown to contain
regions of sequence homology with myosin, the M5 sequence
KGLRRDLDASREAK was analyzed and found, along with
human cardiac myosin, to possess the sequence RRDL, resi-

FIG. 1. Alignment of streptococcal M5 peptides C2A and C3 with the b
heavy chain of human cardiac myosin (21). Identical residues are indicated with
two dots, while a conservative substitution is indicated by a single dot as determined by the FASTA alignment program (Intelligenetics, Mountain View, Calif.). The sequence identified as homologous between C2A, C3, and myosin is
highly conserved (identical) between skeletal and cardiac myosin. The identical
residues are located in the heavy meromyosin fragment of skeletal and cardiac
myosin.

dues 1178 to 1181 (32) (Fig. 1). This segment of cardiac myosin
(Fig. 1) is found in the heavy meromyosin region of the myosin
b heavy-chain rod and is highly conserved (identical) in human
cardiac and skeletal myosins. The identical sequence (RRDL)
between the M protein and myosin is highlighted in Fig. 1.
However, when myosin peptide AEFQKMRRDLEEATLQ
HEA was synthesized and reacted with MAb 10B6 by ELISA
and Western blotting, no reaction was observed (data not
shown). Furthermore, not all M5 peptides containing the
RRDL sequence, such as peptide C1A, reacted with MAb
10B6.
We then tested MAb 10B6 by the ELISA and the immunoblot assay to determine if it could recognize intact myosin.
MAb 10B6 reacted with rabbit skeletal (Fig. 2) and human
cardiac (Fig. 3) myosin but did not react with actin or tropomyosin (Fig. 2). It was also found to react with the heavy
meromyosin fragment of the myosin molecule in the ELISA
but did not react with the light meromyosin fragment (Fig. 2).
Normal mouse sera diluted 1:100 were used as a negative
control in these experiments (Fig. 2 and 3). Although not
shown, an IgG MAb isotype control tested at 10, 20, and 50
mg/ml did not react with myosin in the blot.

FIG. 2. Reaction of MAb 10B6 with myosin. MAb 10B6 (20 mg/ml) and
normal mouse sera (pool from three normal BALB/c mice) (normal mouse sera,
1:100) were reacted with myosin, the light meromyosin fragment (LMM), the
heavy meromyosin fragment (HMM), tropomyosin, and actin by ELISA. Results
with human cardiac and rabbit skeletal myosin were similar.
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inhibitor/A410 of well with MAb plus buffer). Antibodies were tested in duplicate,
and assays were repeated at least twice.
Affinity-purified anti-C3 peptide antibodies. M5 peptide affinity columns were
prepared by coupling 3 mg of peptide with 0.5 g of 6-aminohexanoic acid
N-hydroxysuccinimide ester Sepharose-4B (Sigma). The gel was washed,
blocked, and placed in a column (12). Serum (1 to 0.5 ml) was diluted 1:2 with
PBS (pH 7.2), applied to the gel column, and incubated overnight at 4°C.
Unbound antibody was washed from the column with PBS (pH 7.2). The column
was washed until the eluate read zero at 280 nm in a Beckman spectrophotometer. Bound antibody was then eluted from the column with 0.1 M glycine (pH
2.5). Column fractions were immediately neutralized and read at 280 nm in a
Beckman spectrophotometer. The fractions containing the antibody were dialyzed overnight against PBS (pH 7.2).
Immunoblotting. Western immunoblotting was performed as previously described (14). Human cardiac or rabbit skeletal myosin was separated by electrophoresis under reducing conditions in sodium dodecyl sulfate–10% polyacrylamide gels. The protein was electrophoretically transferred overnight from the
gel to nitrocellulose membranes with a Bio-Rad blotting apparatus. Membranes
were blocked with 2% Tween 20 in PBS (pH 7.2) and reacted with anti-M protein
MAb 10B6. Blots were washed in PBS-Tween buffer, reacted with rabbit antimouse Ig conjugated to peroxidase, washed again, and reacted with 4-chloronaphthol (Sigma) in buffer and H2O2 substrate (13, 14). Normal mouse sera
from BALB/c mice were used as a negative control.
Preparation of antiserum. Seven-week-old female Lewis rats (Harlan
Sprague-Dawley, Indianapolis, Ind.) in groups of three were immunized in the
footpad with 500 mg of peptide or PBS emulsified in Freund’s complete adjuvant
supplemented with 2 mg of heat-killed mycobacteria (strain H37Ra) per ml and
injected intraperitoneally with 2 3 1010 Bordetella pertussis cells (Michigan Department of Public Health, Lansing, Mich.). A group of three animals were
boosted on day 7 with 500 mg of peptide in Freund’s incomplete adjuvant. A
group of three control animals were given adjuvants alone. Animals were euthanized 21 days after immunization. Three rats from the population were euthanized before immunization to provide the preimmune serum control.
Statistical analysis. Means with standard deviations were calculated for ARF,
UNC, AGN, and normal (NOR) serum groups, and serum groups were compared by the Mann-Whitney test to determine significance calculated as onetailed P values. The Mann-Whitney test, also called the rank sum test, is a
nonparametric test that compares two unpaired groups. Since we predicted that
the results for sera from streptococcal diseases would most likely be higher than
normal, we chose the one-tailed P value.
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FIG. 3. Reaction of MAb 10B6 with human cardiac myosin by Western
immunoblot analysis. MAb 10B6 (20 mg/ml) (lane 1) and a control antibody were
reacted with purified myosin by a Western immunoblot analysis. Similar results
were obtained with rabbit skeletal (data not shown) and human cardiac myosin.
Lanes 2 and 3, no reactivity of myosin with normal mouse serum (1:100) and an
isotype control, respectively; lane S, amido black protein stain of the 200-kDa
band of myosin heavy chain. MWS, molecular size standards.

strong reaction with M5 peptide C3 and skeletal or cardiac
myosin (OD 5 1.65) by the ELISA but not with tropomyosin
(OD 5 0.2) or actin (OD 5 0.2). Sera from rats (group of
three) immunized with Freund’s complete adjuvant alone and
the preimmune sera (group of three) showed no reactivity by
the ELISA with any of the antigens tested (OD , 0.2). Rats
immunized with the other 22 M5 peptides (groups of three)
showed no reaction (OD , 0.2) with myosin by the ELISA. All
sera were tested individually in each group by the ELISA.
These results confirmed that epitopes are common between
the M5 peptide C3 (293 to 308) and myosin. Thus, the two
molecules have similar epitopes.
We used ARF sera and peptide C3 to determine if human
antibodies against the class I epitope in peptide C3 cross-react
with myosin. This test was performed with affinity-purified
antibodies to C3 from the sera of three patients with ARF.
Affinity-purified anti-C3 antibodies reacted with the homologous peptide, C3, and with myosin but not with actin or tropomyosin by ELISA (Fig. 6). A pool of 5 normal human sera
was diluted to the same immunoglobulin concentration as the
purified anti-C3 but showed no reaction with peptide C3 (293
to 308) or myosin in the ELISA. Under identical conditions,
sera from a patient with streptococcal pharyngitis and a high
titer of anti-C3 were placed onto the C3 affinity column. The
antibody eluate from the column produced lower reactivity,
but the results demonstrated cross-reactivity of the anti-C3
antibody from UNC with myosin as well as peptide C3. These
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To demonstrate that the antimyosin activity of MAb 10B6
could be adsorbed with sequences found in M protein, a competitive inhibition ELISA was performed in which MAb 10B6
(20 mg/ml) was incubated with various concentrations of either
peptide C2A (residues 254 to 271) or C3 (293 to 308) before it
was reacted with myosin by ELISA. Both M5 peptides, C2A
and C3, inhibited the binding of MAb 10B6 in a dose-dependent fashion. One microgram of either peptide per ml resulted
in 50% inhibition of MAb 10B6 binding to rabbit skeletal
myosin (data not shown) or human cardiac myosin (Fig. 4). M5
peptide C1C2 (residues 241 to 258) showed no inhibition of
MAb 10B6 at any concentration tested (1 to 500 mg/ml; data
not shown). Collectively, our results confirm previous studies
regarding the location of the 10B6 epitope (23) and indicate
that the M5 peptides C2A and C3 (292 to 307) contain the class
I M protein epitope, which is immunologically cross-reactive
with myosin.
Comparison of anti-peptide C3 reactivity of sera from UNC,
ARF, and AGN. In order to determine if there were quantitative differences in IgG responses to peptide C3 in UNC, ARF,
AGN, and NOR sera, titrations of the sera were performed
against peptide C3 in the ELISA. Figure 5 shows the titers of
individual ARF, UNC, AGN, and NOR sera reacted with
peptide C3. There was no significant difference in titers observed for the ARF group versus the UNC group. NOR serum
IgG titers to peptide C3 were ,100, whereas ARF and UNC
titers ranged between ,100 to 3,200 and 12,800, respectively.
The three carditis patients (triangles in Fig. 5) had the highest
IgG titers against peptide C3 in the ARF group; however,
several of the UNC group also had high titers without clinical
evidence of ARF. With two exceptions, the AGN group had a
low or normal IgG response to peptide C3. Statistical comparison of the ARF, UNC, and AGN groups with the normal
group demonstrated that the ARF and UNC groups were
significantly different from the NOR group, while the AGN
group was similar to the NOR group. P values, means, and
standard deviations are reported in the legend for Fig. 5, and
a scattergram of the individual data and group means is shown
in Fig. 5.
To determine if the ability to react with M5 peptide C3
(residues 293 to 308) was a quality possessed by other human
sera containing antimyosin antibodies, serum from nine patients with nonrheumatic myocarditis were pooled and compared with those of the ARF group for reactivity with myosin
and peptide C3 by ELISA. Both groups were found to have
elevated levels of anti-human cardiac myosin antibodies (optical density [OD] 5 1.1), with no apparent difference between
their reactivities in the ELISA. However, a comparison of the
two groups of sera for reactivity to M5 peptide C3 (residues
293 to 308) indicated that the reactivity of the ARF group was
higher (OD 5 0.9) than that of the nonrheumatic group
(OD 5 0.3). The reactivity of the nonrheumatic carditis group
with peptide C3 was similar to that seen with normal serum.
Although a single high-titered serum could have skewed the
results, the data suggest that anti-C3 reactivity is not associated
with all sera demonstrating antimyosin antibody, such as myocarditis patient sera. The anti-C3 reactivity was present only in
serum from patients exposed to streptococci.
Anti-C3 antibodies. We then determined if immunization
with M5 peptide C3 could induce the production of antimyosin
antibodies in Lewis rats, which were chosen because they have
been shown to be susceptible to myosin-induced myocarditis
and streptococcus-induced arthritis. Groups of three rats were
immunized and boosted with M5 peptide C3 (293 to 308) as
well as the other 22 M5 peptides. Antisera (1:100 dilution)
from each of the three C3-immunized rats demonstrated a

CLASS I M PROTEIN EPITOPE AND MYOSIN

4422

QUINN ET AL.

data were similar to those shown for the ARF sera in Fig. 6.
However, compared to UNC sera, 6 times more anti-C3 IgG
and 29 times more anti-C3 IgM were affinity purified from
ARF sera (data not shown). As a control, ARF sera were

FIG. 6. Reaction of affinity-purified anti-C3 antibodies from ARF sera with
streptococcal M5 peptide C3 and myosin. Antibodies to M5 peptide C3 were
affinity purified from the sera of a patient with rheumatic carditis. The purified
antibodies were diluted 1:10 with buffer and reacted with M5 peptides C1C2 and
C3 and with skeletal myosin, actin, and tropomyosin by ELISA. Normal human
sera (five samples) were pooled and tested as the control. Normal and affinitypurified Igs were reacted at the same Ig concentrations. A second ARF carditis
serum was affinity purified and found to react similarly with myosin and peptide
C3 as shown. These data show that human anti-C3 antibodies react with myosin
following streptococcal infection.

passed over a column which contained M5 peptide C1C2 (241
to 258) attached to Sepharose beads. The eluate from this
column showed no reactivity by ELISA with peptide C3 (293 to
308) or myosin. These observations suggest that during a streptococcal infection, an epitope associated with streptococcal M5
peptide C3 may contribute to the antimyosin response observed in UNC and ARF patients. The data show that human
anti-C3 antibodies against the class I epitope react with myosin
and that the levels of anti-C3 antibody purified from peptide
C3 affinity columns were quantitatively much higher in ARF
than in UNC infection.
DISCUSSION

FIG. 5. Scattergram showing the titers of individual ARF, UNC, AGN, and
normal sera tested against peptide C3 by ELISA. Titers of each individual serum
are shown in the scattergram. Sera were diluted 1:100, and twofold dilutions were
performed in PBS. Peptide C3 was coated onto Immunlon 4 microtiter plates at
50 ml/well of a 10-mg/ml solution. The dilutions were added to washed wells, and
the ELISA was performed as described previously. OD was read at 405 nm, and
an endpoint of 0.3 was used to calculate the titer. Triangles represent carditis
patient sera, and a square shows the titer of a normal serum pool from five
normal individuals. Individual sera are represented by single dots. Mean titers (6
standard deviations) are designated by dashed lines and were calculated for the
ARF group (741 6 950), the UNC group (1,825 6 3,562), the AGN group (250 6
292) and the NOR group (112 6 35). A comparison of the ARF, UNC, and AGN
groups with the NOR group yielded the following P values: for ARF versus
NOR, P 5 0.03; for UNC versus NOR, P 5 0.004; and for AGN versus NOR,
P 5 0.336. ARF and UNC groups were significantly different from the NOR and
AGN groups. In addition, the P value for ARF versus AGN was 0.09.

The data in this study support the hypothesis that the class I
epitope of streptococcal M protein is immunologically similar
to myosin. First, anti-M protein MAb 10B6, which recognizes
the class I epitope of M proteins, reacted with cardiac and
skeletal myosins. Synthetic peptides spanning the A, B, and C
repeat regions of M5 protein were reacted with MAb 10B6,
and the two M protein peptides recognized by MAb 10B6,
peptides C2A and C3, contained the consensus amino acid
sequence KGLRRDLDASREAK. Within the common sequence, four amino acids (RRDL) were identical to a site in
human cardiac and skeletal myosins (Fig. 1). The myosin sequence is highly conserved among cardiac and skeletal myosins
and is located in the heavy meromyosin fragment. The crossreactivity is most likely due to its homology with a region in the
heavy meromyosin fragment. The reaction of MAb 10B6 with
the heavy meromyosin fragment (Fig. 2) supports the hypothesis that the myosin cross-reactive epitope recognized by MAb
10B6 is in the heavy meromyosin fragment. It is not clear why
M5 peptide C1A (215 to 232) containing the sequence KGLRRDLD did not react strongly with MAb 10B6 unless the
ELISA reaction time was very extended (hours). The failure of
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FIG. 4. Inhibition of the binding of MAb 10B6 to myosin with M5 peptides.
MAb 10B6 (20 mg/ml) was preincubated with 100 to 0.05 mg of M5 peptide C3
or C2A per ml before being reacted with skeletal myosin by ELISA. Percentage
of inhibition was calculated based on the reaction of MAb 10B6 without inhibitor
and diluted in the buffer used in the inhibition. Results were identical with those
for purified rabbit skeletal and human cardiac myosin. At concentrations of 1 to
500 mg/ml, M5 peptide C1C2 showed no inhibition of MAb 10B6.
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decreased exposure to streptococcal infection, thereby reducing the immune response observed against the class I epitope
(23a). Prior to the use of penicillin, ARF was more prevalent.
The fact that the antimyosin antibody response to the class I
epitope is similar in ARF and UNC patients yet contributes to
the disease in the susceptible host could be due to a host
susceptibility factor. Antimyosin antibodies were shown to deposit in the hearts of only genetically susceptible mice (31).
Penicillin therapy cannot explain the significant differences
between the ARF and AGN groups. Differences between ARF
and AGN sera might be explained by the fact that since the
AGN strains generally do not have the class I epitope, sera
from AGN patients would not be expected to react at levels
equivalent to those of ARF sera against the C3 peptide. The
observation that certain serotypes of streptococci are associated with outbreaks ARF or AGN (4–6) has led to the proposal that unique epitopes or molecules are associated with the
development of ARF. It has been reported that patients with
ARF elicit a serologic response to a class I group A streptococcal infection (5). Furthermore, it is not known if the high
responders to C3 in the UNC group may be at risk for developing ARF from future streptococcal infections.
While there is a close association between the class I
epitope- and the rheumatic fever-producing strains, not all
strains containing this epitope have been associated with ARF.
For example, a reactive 10B6 epitope is also found in M protein isolated from group G streptococci even though this streptococcal group has never been associated with ARF (9, 22). An
explanation why some serotypes of group A streptococci are
recognized by MAb 10B6 and others are not is that the class II
M molecules differ from class I molecules in three amino acid
positions within the conserved C repeat (4).
Most important is the question of whether the class I epitope
and C repeat region are involved in ARF and, if so, what role
they might play in disease. It is important to resolve this question, since a group A streptococcal C repeat vaccine shows
potential for providing broad-based protective immunity
against streptococcal diseases (3, 7, 20). As shown in Fig. 5,
antibodies against the C3 peptide are markers of a class I
streptococcal infection and may be involved in the production
of the disease. If the C repeat region or the class I epitope is a
direct contributor to disease in a susceptible host, it will be
important to distinguish protective from disease-producing
epitopes.
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